Log In
Print this Print this


  Manage Alerts
Collapse Summary General Information
Company Scynexis Inc.
DescriptionNon-immunosuppressive cyclophilin inhibitor
Molecular Target Cyclophilin
Mechanism of ActionCyclophilin inhibitor
Therapeutic Modality 
Latest Stage of DevelopmentPhase II
Standard IndicationHepatitis C virus (HCV)
Indication DetailsTreat HCV genotype 1 infection in treatment-naïve patients; Treat HCV infection
Regulatory Designation
PartnerWaterstone Pharmaceuticals Ltd.

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments





 Deals Details
Get a free BioCentury trial today